FDA clears RapidAI's pulmonary embolism software

2020 03 04 21 21 6197 Artificial Intelligence Ai Hand 400 20200304215813

The U.S. Food and Drug Administration (FDA) has cleared RapidAI's Rapid RV/LV, a program that calculates heart metrics associated with pulmonary embolism.

The software assesses the ratio between the right ventricle and the left ventricle, a key indicator of pulmonary embolism severity. Key benefits of Rapid RV/LV include identifying patients with possible right heart strain, reducing time to diagnosis, and reducing variability in RV/LV measurements, according to the company.

Page 1 of 651
Next Page